Form 4: MEI Pharma Director Steven Wood Receives 20,000 Stock Options

MEI Pharma, Inc. Director Steven D. Wood was granted 20,000 stock options with an exercise price of $3.07, effective July 15, 2025.

Summary

• Steven D. Wood, a Director of MEI Pharma, Inc., was granted 20,000 stock options.
• The stock options have an exercise price of $3.07 per share.
• The grant date and exercisable date for these options is July 15, 2025.
• The options are set to expire on July 15, 2035.
• Mr. Wood directly owns 4,359 shares of MEI Pharma common stock.
• He indirectly beneficially owns 67,733 shares of common stock through GreenWood Builders Fund III, LP, where he serves as Chief Investment Officer of the investment advisor, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued alignment between the board and shareholder interests, and is a standard compensation practice. No negative information is present.

Positives

• The grant of 20,000 stock options aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Future Outlook

NA

Management Comments

• Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025.

Industry Context

This is a standard compensation practice for non-employee directors in the biotechnology and pharmaceutical industry, aiming to align their long-term interests with the company's performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common compensation component across publicly traded companies, particularly in the biotech sector, where long-term incentives are crucial.
• While specific grant sizes vary by company size, market capitalization, and individual director responsibilities, a grant of 20,000 options for a director at a company like MEI Pharma is within typical ranges for similar-sized biotech firms, such as those with market caps under $500 million.
• Companies like Xencor (XNCR) or Geron Corporation (Gern) often use similar equity-based compensation structures for their non-executive board members to incentivize strategic oversight and growth.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

Keywords

MEI Pharma, MEIP, Steven D. Wood, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership